Compare Grab Holdings Ltd. (GRAB) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs McKesson Corporation — how do they compare? Grab Holdings Ltd. trades at $3.62 (market cap $15.26B), while McKesson Corporation trades at $878.8 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 6.9× Grab Holdings Ltd.'s market cap, and McKesson Corporation pays a 0.42% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals.
| GRAB | MCK | |
|---|---|---|
Market Cap | $15.26B | $105.14B |
Sector | Technology | Health |
52-Week High | $6.45 | $995.69 |
52-Week Low | $3.27 | $659.01 |
Enterprise Value | $10.99B | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.605, down 1.77% today, but maintains a bullish technical trend. The company reported strong Q2 2026 earnings, beating estimates with $0.06 EPS, and raised full-year revenue guidance to 22-23% growth. Positive analyst sentiment includes an average price target of $5.86, implying 58% upside. Fundamentals show improving profitability, with net income turning positive in 2025 at $268 million and margins expanding.
Outlook is positive given earnings momentum and raised guidance, but risks include high valuation multiples, insider selling, and competitive pressures in Southeast Asia. The stock offers growth potential if execution continues, yet investors should weigh valuation against profitability sustainability and market volatility.
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
